Among people with osteoarthritis or rheumatoid arthritis who undergo total knee replacement, continuous preoperative opioid use is associated with an increased risk for adverse outcomes, study findings suggest.
48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.
The increased risk for gout flares following receipt of the aluminum-free recombinant zoster vaccine is not unique to this vaccine but is instead associated with vaccination in general, regardless of the adjuvant used, US researchers report.
People with osteoarthritis have a significantly higher risk for developing cardiovascular disease than those without, and the use of nonsteroidal anti-inflammatory drugs mediates a considerable proportion of this association, researchers report.
A systematic review has identified several factors predicting successful discontinuation of biologic DMARDs in people with rheumatoid arthritis, including low disease activity and good physical function.
Findings from the phase II ASSET trial suggest that patients with diffuse cutaneous systemic sclerosis who are treated with abatacept do not experience significantly greater improvements in skin disease than those given placebo.
Rheumatoid arthritis (RA) patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.
The likelihood of maintaining remission following etanercept withdrawal is highest among rheumatoid arthritis patients with the greatest degree of remission prior to the start of withdrawal and decreases with decreasing remission status, research shows.